Sodium–glucose cotransporter-2 (SGLT-2) inhibitors, also called gliflozins, such as canagliflozin, dapagliflozin, and empagliflozin, are popular in the treatment of both type 1 and T2DM [40,41,42]. Here, SLC5A2 is linked to type 2 diabetes mellitus.